The offer of securities by Noxopharm Limited [ABN 50 608 966 123] (Noxopharm or the Company) is made in the Company’s replacement prospectus dated, and lodged with the Australian Securities and Investments Commission on, 24 June 2016 (Prospectus).
The Prospectus is available on the Noxopharm website at www.noxopharm.com/prospectus. You also may email info@noxopharm.com to request a copy of the Prospectus to be sent to you.
Before deciding to acquire shares, readers should read and consider the Prospectus in its entirety and, if in any doubt, consult their professional advisors. Any decision by a person to apply for securities of Noxopharm should be made on the basis of the information contained in the Prospectus including the risks disclosed therein and independent assessment as to whether to invest, and not in reliance on any information contained in these FAQ’s. Eligible persons wishing to acquire Noxopharm shares will need to complete an application form which accompanies a copy of the Prospectus.
What is the Initial Public Offering (IPO)?
The IPO is an offer by Noxopharm to investors to apply for up to 30,000,000 shares (New Shares) at an issue price of $0.20 per New Share to raise $6,000,000.
Who is the Offer made to?
The Offer of New Shares to investors under the Prospectus is made to:
Do I fall under the Broker Offer or General Offer?
If you have received a firm allocation of New Shares from your broker, then you will be treated as a Broker Offer applicant in respect of that allocation and you will need to apply using a personalised Broker Offer Application form obtained from your Broker.
Otherwise you can participate in the Offer under the General Offer by completing the General Offer Application form provided in the Prospectus. Details on application lodgement and monies are included in the General Offer application form.
How many shares am I allowed to apply for?
To calculate the amount of the Application Monies, multiply the number of Shares being applied for by the offer price per New Share ($0.20).
Note that Noxopharm may reject or not accept an application, in part or in whole or allocate fewer New Shares than applied for.
When does the Offer open and when does it close?
The Offer opens at 9.00am (AEST) on 24 June 2016 and is expected to close at 5.00pm (AEST) on 18 July 2016, unless closed earlier or extended without notice. Applications for New Shares must be received no later than 5.00pm AEST on 18 July 2016.
When do I receive notification if my application for New Shares has been successful?
Allocation of New Shares between the Broker Offer and General Offer will be determined by the Company at its discretion in consultation with the Lead Manager.
Holding statements are anticipated to be distributed either by the Company’s share registry or from your broker (if you are CHESS sponsored) following ASX listing and the New Shares being issued.
What happens if I do not have a HIN (Holder Identification Number) or do not provide it on the Application Form?
The share registry will issue the New Shares to you on a SRN (Security Holder Reference Number) and will provide you with an issuer sponsored holding statement for your record confirming your SRN and number of shares held.
What happens if the Offer does not proceed?
Noxopharm reserves the right to withdraw the Offer at any time prior to the allotment of New Shares. If the Offer does not proceed, monies received in respect of applications for New Shares will be refunded. No interest is paid on monies refunded as a result of the withdrawal of the Offer.
How will proceeds of the Offer be used?
A detailed breakdown of the intended use of the funds raised from the offer can be found on pages 61 and 62 of the Prospectus.
How do I apply for New Shares?
Broker Offer If you have received a firm allocation of New Shares from your broker, then you will be treated as a Broker Offer applicant in respect of that allocation and you will need to apply using a personalised Broker Offer application form obtained from your broker.
Applicants under the Broker Offer must lodge their personalised Broker Offer application form and application monies with the relevant broker in accordance with the relevant broker’s directions in order to receive their firm allocation. Broker Offer application forms must be completed in accordance with instructions given to you by your broker and the instructions set out on the Broker Offer application form.
Do not send the Broker Offer application forms or payment to the Share Registry.
Applicants under the Broker Offer must pay the application amount for the New Shares applied for under the Broker Offer to their broker in accordance with the instructions provided by their broker. The Company, the Lead Manager and the Company’s share registry take no responsibility for any acts or omissions committed by your broker in connection with your application.
The Company, in consultation with the Lead Manager, reserves the right to reject any application which is submitted by a person who they believe is ineligible to participate in the Broker Offer.
General Offer If you have not received a firm allocation of New Shares from your broker, you can apply under the General Offer. Applications under the General Offer may be made, and will be accepted, in one of the following forms:
Instructions for completing and lodging the General Offer application form and paying the application amount are set out in the General Offer application form.
Unless you have made arrangements with your broker or the Lead Manager, the completed General Offer application form and payment should be posted to:
Noxopharm Limited C/ - Automic Registry Services Pty Ltd PO Box 2226 STRAWBERRY HILLS NSW 2012 AUSTRALIA
For hand delivered applications (please do not use this address for mailing purposes) deliver to:
Noxopharm Ltd IPO C/- Automic Registry Services Suite 310, Level 3, 50 Holt Street SURRY HILLS NSW 2010
To make payment via cheque: Payments are to be made in Australian currency by a cheque drawn on an Australian branch of an Australian Bank.
To make payment by BPay or by Electronic Funds Transfer (EFT) payment: Please email your completed Application Form to noxopharm@automic.com.au and preferred payment method. The registry will then contact you with your unique payment reference number and will outline the procedure for making payment by BPay or EFT. Applicants should be aware of their financial institution’s cut-off time. It is the Applicant’s responsibility to ensure funds are submitted correctly by the Closing Date and time.
It is your responsibility to ensure funds are submitted correctly.
Applying for New Shares generally No applications for securities will be accepted nor will securities be issued on the basis of the Prospectus earlier than seven days after the lodgement of the Prospectus with ASIC.
Applications for securities referred to in the Prospectus must be made in accordance with the terms and conditions of the Prospectus. Applications for securities must be made on an application form that accompanies a complete hard copy of the Prospectus or the complete unaltered electronic version of the Prospectus.
It is your responsibility to ensure that application forms and payment are mailed in time to allow delivery in accordance with the terms and conditions of the Prospectus. It is also your responsibility to ensure sufficient funds are available upon presentation of cheques. If returning your application for to your broker, please allow sufficient time for your broker to receive and process your application.
The Company, the Lead Manager and the Company’s share registry take no responsibility for lost or delayed mail, or misprocessed acceptances and payments, or errors or delays by brokers. The Company, in consultation with the Lead Manager may, but is not obliged to, accept late applications and acceptances.
To the extent permitted by law, an application under the Offer is irrevocable. If the amount received as application amount is less than the amount payable for the New Shares accepted or applied for, the Company may (but is not obliged to) treat the acceptance or application as being for the number of New Shares represented by the amount received and issue fewer New Shares than were applied for. The Company, in consultation with the Lead Manager, may correct or fill in any application or acceptance form and/or treat as valid and give effect to an application or acceptance form notwithstanding any error or that any information is incomplete.
The Company, in consultation with the Lead Manager, may reject or not accept an application in part or in whole or to allocate fewer New Shares than applied for. If acceptances and applications in excess of $6 million are received, the Board reserves the right not to accept (in whole or in part) or to scale back applications at its discretion in consultation with the Lead Manager. If an application is rejected or not accepted in whole or in part or is scaled back, the relevant amount will be refunded to the applicant as soon as practicable after completion of the Offer without interest.
Who do I contact if I need assistance?
Phone: 1300 288 664 or +61 2 9698 5414 Email: info@noxopharm.com
